Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Acne

Therapeutic area intelligence for Acne with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Companies
2

Companies

Alembic Pharmaceuticals →
Sun Pharma →

Assets

Absorica →
Dermatology →
Tretinoin →

Recent signals(3)

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for Absorica by Sun Pharma

The FDA has accepted a supplemental application for Absorica, an isotretinoin product from Sun Pharma.

RegulatoryJune 18, 2026

FDA Accepts Supplement for ABSORICA LD by Sun Pharma

The FDA has accepted a supplemental application for ABSORICA LD, an isotretinoin product by Sun Pharma.

StrategyJune 18, 2026

FDA Grants Approval for Tretinoin ANDA214590 by Alembic

The FDA has granted approval for Alembic's Abbreviated New Drug Application (ANDA) for Tretinoin.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.